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Abstract
The development of coagulation abnormalities is common in patients with sepsis. Sepsis-associated coagulopathy (SAC) is
typically diagnosed by prothrombin time (PT) prolongation or elevated international normalized ratio (INR) in conjunction with
reduced platelet count. INR is also used to monitor warfarin-treated patients. However, due to the different natures of SAC and
warfarin anticoagulation, it is likely that the same INR value provides different information in these two patient populations. The
purpose of this study was to compare measures of coagulation function and clotting factor levels in patients with SAC to those
observed in patients receiving warfarin anticoagulation. Deidentified plasma samples were collected at baseline from patients
diagnosed with SAC and from patients receiving warfarin. These plasma samples were evaluated for PT/INR, activated partial
thromboplastin time (aPTT), fibrinogen, and functional and immunologic levels of factors VII, IX, and X. Both aPTT and fibrinogen
correlated with INR in patients with SAC, but not in patients treated with warfarin. Factors VII, IX, and X showed an inverse
relationship with INR in the anticoagulated patients; however, no relationship between factor level and INR was observed in
patients with SAC. Distinct patterns of coagulopathy were observed in patients with SAC and patients receiving warfarin
anticoagulation, and equivalent INR values were associated with distinct coagulation profiles in the two patient groups. These
results suggest that an abnormal INR provides different information about the coagulation status in patients with disseminated
intravascular coagulation than in patients receiving warfarin. This may indicate that an equivalently increased INR predicts different
bleeding risks in these two patient groups.
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Introduction
Sepsis is a severe systemic response to infection characterized
by an overwhelming inflammatory response. This syndrome is
a significant cause of morbidity and mortality both within the
United States and worldwide, with “septicemia” listed by the
Centers for Disease Control as the 11th most common cause of
death in the United States in 2010.1 Sepsis occurs across a wide
spectrum of severity, and estimates of mortality are variable,
ranging from 14.7% to 29.9%,2,3 to up to 80% for more severe
forms of sepsis.4
The patient’s own immune system plays a key role in the
pathology of sepsis, both in the initial stage of hyperimmune
response and in the subsequent phase of immune paralysis.
While robust activation of the immune and inflammatory sys-
tems is necessary for the eradication of bacteria, this excessive
response may also prove detrimental to the host.3-6 In addition
to contributing to the development of blood pressure collapse,
shock, and organ failure, the excessive inflammation observed
in sepsis contributes to the development of coagulopathy.
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Extensive cross talk occurs between inflammation and coa-
gulation.7 In sepsis, bacterial components, particularly lipopo-
lysaccharide, elicit a vigorous inflammatory response. This
includes production of high levels of inflammatory cytokines,
such as interleukin (IL)-6, IL-1b, and tumor necrosis factor a,
which induce tissue factor (TF) expression on intravascular
cells such as monocytes, macrophages, and the endothe-
lium.8-14 The introduction of TF into the circulation activates
the extrinsic pathway of the coagulation cascade and is gener-
ally considered to be the major initiator of coagulation in this
patient population.15,16 Consequently, a significant number of
patients hospitalized with sepsis develop coagulation
abnormalities.17
The coagulation abnormalities observed in patients with
sepsis range from perturbations in laboratory values to severe
overt disseminated intravascular coagulation (DIC), an
acquired coagulation disorder with high mortality that is char-
acterized by both thrombotic and bleeding complica-
tions.3,16,18,19 In DIC, widespread activation of coagulation
leads to fibrin deposition in the microvasculature and subse-
quent organ failure. This process consumes platelets and coa-
gulation factors, leading to a risk of significant and potentially
fatal bleeding. Development of DIC significantly increases the
risk of death in patients with sepsis,16-18,20-22 with mortality
due to DIC often estimated at 40% or above.16
Disseminated intravascular coagulation is graded through
the application of a scoring system published by the Interna-
tional Society of Thrombosis and Hemostasis (ISTH).23 This
algorithm assigns patients with a predisposing condition such
as sepsis with a DIC score based on reduced platelet count,
prolonged international normalized ratio (INR), elevated fibrin
degradation products (ie, D-dimer), and decreased fibrinogen.
In clinical practice, however, simplified schemes are often used
to identify patients with sepsis-associated coagulopathy (SAC),
a less rigidly defined term that indicates the presence of coa-
gulation dysfunction of variable severity in patients with sepsis.
Typically, identification of SAC is made on the basis of an
elevated prothrombin time (PT) or INR in conjunction with
thrombocytopenia.
As INR is one of the key parameters used clinically to
identify patients with SAC, it is important to understand the
appropriate interpretation of this measure in this specific
patient population. Prolonged PT or elevated INR is generally
indicative of a hypocoagulable state; however, patients present-
ing with SAC with an elevated INR are at risk of complications
due to both thrombosis and bleeding.
Elevated PT or INR is reported in 90% or more of patients
with sepsis with severe disease.24-26 Prolonged PT and elevated
INR are associated with increased mortality and poor clinical
outcome in patients with sepsis25,27 as well as in other critically
ill or injured patient populations.28,29 Elevated PT–INR (typi-
cally INR 1.2) is often a component of the inclusion criteria
for clinical trials in patients with SAC.30,31 The majority of the
elevated INRs within this patient population have been
reported to fall into the range of 1.6 to 2.5.29 Other changes
in global coagulation parameters, including activated partial
thromboplastin time (aPTT)17,24-26,32,33 and whole-blood coa-
gulability as measured by thromboelastography,26,32,33 are also
often reported in patients with sepsis as well as in other criti-
cally ill patient populations.
Despite the clear evidence that significant changes to the
overall coagulation profile occur in sepsis, changes in the levels
of individual coagulation factors in patients with SAC are less
well established. Reduced levels of coagulation factors includ-
ing factors (F) II, FV, FVII, FX, and FXII compared to normal
individuals have been reported in patients with SAC.24 How-
ever, these results demonstrated no discernible relationship to
standard coagulation tests and are highly variable between
studies.24,32,33
The PT/INR was designed to monitor the anticoagulation
status in patients treated with warfarin and is widely used
clinically for this purpose. Patients treated with warfarin are
typically considered appropriately anticoagulated with an INR
of between 2 and 3, and regular adjustments to drug dosage are
made to maintain the INR within this range. A study of the
relationship of INR to the risk of severe bleeding in patients on
warfarin revealed that the INRs associated with severe bleeding
in this population are more elevated than those observed in
patients with sepsis, with a mean INR of 5.9 at the time of the
bleed and 3.0 at the clinic visit prior to the bleed.34 A study of
the relationship of serial INR levels to severe bleeding in
patients receiving warfarin anticoagulation found that
warfarin-treated patients hospitalized with severe bleeding
showed an elevated INR compared to nonbleeding patients
(5.9 + 5.9 vs 2.3 + 0.7) as well as higher INRs before the
event of the bleed (3.0 + 1.2 vs 2.1 + 0.8).34
The difference in INR levels at which bleeding occurs in
patients treated with warfarin and patients with SAC and the
fact that patients with SAC with an elevated INR indicative of
hypocoagulability experience both thrombotic and bleeding
complications suggest that the information provided by this
common laboratory test may be significantly different in these
two patient populations. The purpose of this study was to com-
pare the relationship of laboratory coagulation tests and levels
of individual coagulation factors with INR in patients with
SAC to the relationships observed in warfarin-treated patients.
Materials and Methods
Control Plasma Samples
Frozen, citrated plasma samples from healthy individuals, ages
18 to 55, nonsmokers, with no known medical conditions, were
purchased from George King Biomedical (Overland Park, Kan-
sas) and stored at 80C prior to analysis.
Deidentified Patients Treated With Warfarin and DIC
Samples
Citrated, deidentified plasma samples were collected from the
clinical laboratory under an institutional review board–
approved protocol. Samples were collected from discarded
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specimens and no modification was made to patient care during
this sample collection. Limited information was available to
accompany each specimen including diagnosis and treatment.
Samples were collected from patients receiving warfarin anti-
coagulation (n ¼ 112) and patients with SAC, defined as overt
or nonovert DIC by the ISTH scoring criteria (n ¼ 78).
Clotting Assays: PT and aPTT and Fibrinogen Assays
Prothrombin time, aPTT, and fibrinogen were measured using
standard operating procedures on an ACL-300 or ACL-ELITE
automated coagulation analyzer (Instrumentation Laboratory,
Bedford, Massachusetts). This instrument uses an optical
method to detect clot formation in a plasma sample. For aPTT,
Platelin (Diagnostica Stago, Parsippany, New Jersey) was used
along with 0.025 M CaCl2 to recalcify the citrated plasma. For
PT/INR and fibrinogen, Recombiplastin (Instrumentation
Laboratory) was used.
Coagulation Factor Antigenic Levels
Antigenic levels of FVII, FIX, and FX were measured using
commercially available enzyme-linked immunosorbent assay
(ELISA) kits (Hyphen BioMed, Neuville-Sur-Oise, France),
performed according to the manufacturer’s instructions.
Coagulation Factor Activity Assays
Activity levels of individual coagulation factors were evaluated
using modified 1-step PT or aPTT methods. Clot formation in
these tests was evaluated mechanically using an ST4 coagula-
tion analyzer (Diagnostica Stago).
For FVII, a 1-step PT assay was used. Patient samples were
diluted 1:10 in Owren Veronal buffer (Dade Bennng Siemens:
Erlangen, Germany). 50 ml of factor-deficient plasma (Aniara,
Westchester, Ohio) and 50 mL of diluted patient sample were
warmed to 37C in a cuvette with a metal mixing ball for 180
seconds. 100 ml of Dade Innovin PT reagent (Siemens Healthcare
Diagnostics, Newark, Delaware) was added and the time to clot
was recorded. Factor VII level was calculated in each sample
relative to normal human plasma based on a standard curve.
For FIX and FX, a 2-step aPTT assay was used. Patient
samples were diluted 1:20 in Owren Veronal buffer. 50 ml of
diluted sample, 50 mL of aPTT reagent, and 50 mL of factor-
deficient plasma (Aniara) were warmed to 37C in a cuvette
with a metal mixing ball for 300 seconds. 50 ml of CaCl2 was
added and the time to clot was recorded. Factor IX and FX
levels were calculated in each sample relative to normal human
plasma.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism soft-
ware (La Jolla, California). Patients were categorized into
groups based on INR levels, with groups of INR of less than
1.5, 1.5 to 1.9, 2 to 2.9, and 3 or greater. For both patient
populations, variability of every parameter based on INR was
assessed using the Kruskal-Wallis 1-way analysis of variance
(ANOVA) and Dunn multiple comparison test, with a ¼ .05 as
the cutoff for significance. Plots of test result or factor level
versus INR were also created for both patient groups, and trend
line fit was assessed. Spearman correlation coefficients were
determined for relationships between coagulation factor levels
and coagulation test results for both patient groups.
Results
The aPTT was measured in both warfarin-treated patients and
patients with SAC, as shown in Table 1 and Figure 1A and B.
Overall, significant variation in aPTT based on INR was
observed in both patients treated with warfarin (P ¼ .019) and
patients with SAC (P < .0001). In patients treated with war-
farin, a significant difference was observed between patients
with a subtherapeutic INR of 1.5 to 1.9 and patients with a
supertherapeutic INR of greater than 3 (P ¼ .034; Figure
1A). In patients with SAC, aPTT showed a stepwise increase
with increasing INR, although statistical significance was only
reached between patients with an INR of less than 1.5 and
patients with an INR of 1.5 to 1.9 (P ¼ .0001), 2 to 2.9 (P <
.0001), and 3 or greater (P ¼ .001; Figure 1B). Although the
aPTT values for patients with an INR of less than 2 were
similar between the two patient populations, the maximum
observed aPTTs were markedly higher in the patient with SAC
population than in patients treated with warfarin. Scatterplots
of aPTT versus INR were also generated for both patients
treated with warfarin and patients with SAC, and linear fit was
Table 1. Relationship of aPTT and Fibrinogen to INR in Warfarin-Treated Patients and Patients With SAC.
INR
Range

















<1.5 40.4 + 2.5 38.2 33.5 + 0.7 32.9 447 + 39 430 563 + 36 515
1.5-1.9 36.8 + 2.2 33.5 43.2 + 1.6 43.4 415 + 36 361 478 + 43 472
2-2.9 36.6 + 1.5 33.7 60.0 + 6.5 55.1 555 + 38 582 339 + 84 223
3 43.7 + 2.4 40.8 97.1 + 11.6 92.9 590 + 38 588 352 + 186 195
Abbreviations: aPTT, activated partial thromboplastin time; FIB, fibrinogen; INR, international normalized ratio; SAC, sepsis-associated coagulopathy; SEM,
standard error of the mean.
Walborn et al 1035
assessed. For patients treated with warfarin, the fit was poor fit
(R2 ¼ 0.005) and the slope was not significantly nonzero (P ¼
.444). For patients with SAC, the R2 was 0.6789 and the slope
was significantly nonzero (P < .0001).
Fibrinogen was measured in both patients treated with war-
farin and patients with SAC, as shown in Table 1 and Figure 1B
and C. Overall, significant variation was observed in patients
treated with warfarin (P¼ .0005; Figure 1C), but not in patients
with SAC (P ¼ .075; Figure 1D). For patients treated with
warfarin, the difference was significant between patients with
an INR of less than 5 and an INR of 3 or greater (P¼ .0400), an
INR of 1.5 to 1.9 versus an INR of 2 to 2.9 (P ¼ .0080), and an
INR of 1.5 to 1.9 versus an INR of greater than 3 (P ¼ .0077).
Scatterplots of fibrinogen versus INR were also generated for
both patients treated with warfarin and patients with SAC, and
linear fit was evaluated. The fit was poor for both patients
treated with warfarin (R2 ¼ 0.05376) and patients with SAC
(R2 ¼ 0.08381), although the slope was significantly nonzero
for both the patient groups (P ¼ .0075 for patients treated with
warfarin and P ¼ .0107 for patients with SAC).
In addition, the levels of coagulation factors FVII, FIX, and
FX were measured in patients treated with warfarin and
patients with SAC as well as in a population of 50 healthy
controls, as shown in Figure 2. Immunologic levels of all fac-
tors were determined using commercially available ELISA
methods, while functional levels were determined using clot-
based methods. Coagulation levels in the both patients treated
with warfarin and patient with SAC populations were com-
pared to levels in the control population. Both functional and
antigenic levels of all three factors were found to be signifi-
cantly reduced in both patients treated with warfarin and
patients with SAC compared to healthy controls.
The relationship of coagulation factor level to INR was
assessed for each factor in both patients with SAC and
warfarin-treated patients, as shown in Figure 3 and Table 2. Dif-
ferences in factor levels based on INR group were assessed using
theKruskal-WallisANOVA for nonparametric data,witha¼ .05
as the cutoff for significance. Differences between individual
groups were analyzed using Dunn’s multiple comparison test.
Statistical significance was not achieved for comparison of
antigenic levels of FVII between INR groups for either patient
groups (data not shown). Significant variation in functional FVII
based on INR was seen in both patients treated with warfarin (P
< .0001) and patients with SAC (P ¼ .0004; Figure 3A and B
Figure 1. Relationship of aPTT and fibrinogen to INR in warfarin-treated patients and patients with SAC. Top, Activated partial thromboplastin
time in (A) warfarin-treated patients and (B) patients with SAC stratified by INR group. Bottom, Fibrinogen in (C) warfarin-treated patients and
(D) patients with SAC. Comparison was made using the Kruskal-Wallis 1-way ANOVA and Dunn multiple comparison test with a ¼ .05 as the
cutoff for significance (indicated by asterisk). ANOVA indicates analysis of variance; aPTT, activated partial thromboplastin time; INR, inter-
national normalized ratio; SAC, sepsis-associated coagulopathy.
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and Table 2). For patients treated with warfarin, significant dif-
ferences were observed for patients with an INR of <1.5 versus 2
to 2.9 (P < .0001), <1.5 versus >3 (P < .0001), 1.5 to 1.9 versus 2
to 2.9 (P ¼ .0331), and 1.5 to 1.9 versus >3 (P < .0001). For
patients with SAC, the difference was only significant for
patients with INRs of <1.5 versus 1.5 to 1.9. The linear fit of
FVII versus INR was also evaluated. Fit was reasonably strong
for warfarin-treated patients (R2 ¼ 0.424) with a significantly
nonzero slope (P < .0001), but poor for patients with SAC (R2¼
0.018) with a not significantly nonzero slope (P ¼ .837).
For FIX (Figure 3C and D and Table 2), comparable results
were observed for both functional and antigenic factor levels.
Significant variation in functional FIX based on INR was seen in
warfarin-treated patients (P < .0001), but not in patients with
SAC (P ¼ .6097). For warfarin-treated patients, significant dif-
ferences were observed for patients with an INR of <1.5 versus 2
to 2.9 (P¼ .0008), <1.5 versus >3 (P¼ .0004), 1.5 to 1.9 versus
2 to 2.9 (P ¼ .0449), and 1.5 to 1.9 versus >3 (P < .0092). The
linear fit was reasonably poor for both warfarin-treated patients
(R2 ¼ 0.165) and patients with SAC (R2 ¼ 0.095), with a sig-
nificantly nonzero slope for both populations (P < .0001 for
warfarin-treated patients and P ¼ .006 for patients with SAC).
As with FIX, comparable results were observed for the func-
tional and antigenic levels of FX (Figure 3E and F and Table 2).
Figure 2. Antigenically and functionally determined levels of coagulation factors in warfarin-treated patients and patients with SAC compared to
healthy controls. For each factor, comparison was made between healthy controls and warfarin-treated patients and healthy controls and
patients with SAC using the Mann-Whitney t test with P < .05 as the cutoff for significance (indicated by asterisk). INR indicates international
normalized ratio; SAC, sepsis-associated coagulopathy. Panels A and B show antigenic and functional levels of FVII, respectively. Panels C and D
show antigenic and functinal levels of FIX respectively. Panels E and F show antigenic and functinal levels of FX, respectively.
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Significant variation in functional FX based on INR was seen
in both warfarin-treated patients (P < .0001) and patients with
SAC (P ¼ .0003). For warfarin-treated patients, significant
differences were observed for patients with an INR of <1.5
versus 2 to 2.9 (P < .0001), <1.5 versus >3 (P < .0001), 1.5
to 1.9 versus 2 to 2.9 (P ¼ .0005), and 1.5 to 1.9 versus >3
(P < .0001). For patients with SAC, significant differences
were observed for patients with an INR <15 versus 1.5 to 1.9
(P ¼ .002) and <1.5 versus >3 (P ¼ .036). The linear fit was
reasonably good for warfarin-treated patients (R2 ¼ 0.5145),
but poor for patients with SAC (R2 ¼ 0.141), with a signifi-
cantly nonzero slope for both populations (P < .0001 for
warfarin-treated patients and P¼ .0007 for patients with SAC).
The correlations between levels of all factors were analyzed
for both the warfarin-treated and SAC patient groups. Spear-
man correlation coefficients were analyzed with a ¼ .05 as the
cutoff for significance. The observed patterns of correlations
were markedly different for both warfarin-treated patients and
Figure 3. Relationship of functional coagulation factor levels to INR in warfarin-treated patients and patients with SAC. Functional levels of
factors VII (A and B), IX (C and D), and X (E and F) in warfarin-treated patients and patients with SAC stratified by INR group. Comparison was
made using the Kruskal-Wallis 1-way ANOVA and Dunn multiple comparison test with a ¼ .05 as the cutoff for significance. ANOVA indicates
analysis of variance; INR, international normalized ratio; SAC, sepsis-associated coagulopathy.
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patients with SAC. For warfarin-treated patients, significant
and often strong correlations were observed between INR and
both functional and antigenic levels of the coagulation factors.
Correlations were stronger with functional factor levels than
with antigenic factor levels. In this patient population, the lev-
els of FVII, FIX, and FIX were highly correlated with each
other as well. Strong correlations were also seen between anti-
genic and functional levels of all three coagulation factors. In
contrast, fewer correlations were observed overall in patients
with SAC, and the observed correlations were overall weaker.
A strong correlation was observed between INR and aPTT in
the patients with SAC, whereas no correlation was observed in
the warfarin-treated patients. In the patients with SAC, both
INR and aPTT correlated significantly with the functional, but
not antigenic, levels of FVII, FIX, and FX, with the strongest
correlations observed with functional FX for both tests. Fewer
correlations between the levels of coagulation factors were
observed in patients with DIC compared to warfarin-treated
patients. The only strong correlation observed between coagu-
lation factors in patients with SAC was between the functional
and antigenic levels of FX. Functional and antigenic levels of
FVII and FIX showed no correlations with each other.
Discussion
Markedly different relationships between INR and other
laboratory coagulation tests and coagulation factor levels were
observed in patients with SAC compared to patients receiving
warfarin anticoagulation. In patients with SAC, increased INR
was associated with increased aPTT. This supports the hypoth-
esis that the coagulation dysfunction indicated by a given INR
level is different in warfarin-treated patients, where changes in
INR are the result of a targeted disruption to the coagulation
cascade, than in patients with SAC, where an elevated INR is
indicative of a more diffuse insult to the coagulation system.
Functional and antigenic levels of coagulation FVII, FIX,
and FX were decreased in both warfarin-treated patients and
patients with SAC compared to healthy controls. However, the
pattern of decrease in factor levels was markedly different
between the two patient groups. In warfarin-treated patients,
the decrease in factor levels corresponded strongly with an
increase in INR. In contrast, the factor levels in patients with
SAC were uniformly low across all INR levels; additional
increases in INR did not correspond with an additional drop
in coagulation factor levels.
When correlations between all coagulation tests and factor
levels were assessed, strikingly different patterns were
observed in both patients with SAC and warfarin-treated
patients. In warfarin-treated patients, both functional and anti-
genic levels of FVII, FIX, and FX showed strong correlations
with each other. The highly correlated levels of coagulation
factors in these patients are a reflection of the unified mechan-
ism by which warfarin inhibits coagulation. These factors also
correlate strongly with INR, the test designed to monitor the
effects of warfarin on the coagulation cascade. In contrast,
minimal significant correlations were observed between coa-
gulation factors in patients with SAC. While coagulation factor
levels were overall decreased compared to healthy controls in
this patient population, the patient-to-patient variation in the
nature of this decrease was high, indicated by the lack of cor-
relation between factor levels. Furthermore, the levels of indi-
vidual coagulation factors were not predictable based on INR
in the SAC patient cohort.
This study supports the hypothesis that the meaning of an
elevated INR is substantially different in warfarin-treated
patients than in patients with SAC. In warfarin-treated patients,
an elevated INR suggests a uniform and predictable reduction
in the detectable and functional levels of multiple coagulation
factors without an accompanying alteration in the other global
coagulation parameter of aPTT. In this patient population, ele-
vated INR is solely a measure of a specific type of hypocoagul-
ability induced by warfarin in order to prevent thrombotic
complications. In contrast, an elevated INR in patients with
SAC provides different information accompanied by global
coagulation dysfunction, suggested by the strong correlation
Table 2. Relationship Functional Levels of Factors VII, IX, and X to INR in Warfarin-Treated Patients and Patients With SAC.
INR
Warfarin-Treated Patients Patients With SAC
Mean Median SEM n Mean Median SEM n
Factor VII, functional (%) <1.5 59.0 59.3 3.1 26 101.7 104.3 3.4 46
1.5-1.9 48.7 46.9 3.0 29 72.2 72.8 4.1 19
2-2.9 37.0 34.8 2.1 33 93.2 85.9 16.1 10
3 20.2 19.6 3.5 12 88.4 112.5 28.6 3
Factor IX, functional (%) <1.5 85.4 88.6 4.2 29 82.3 84.8 3.1 46
1.5-1.9 72.57 73.77 4.9 30 78.3 77.0 3.4 19
2-2.9 66.4 70.8 4.7 34 80.0 80.2 7.4 10
3 53.5 55.6 4.1 12 74.8 81.9 13.8 3
Factor X, functional (%) <1.5 65.4 71.6 3.3 30 91.3 92.1 1.8 46
1.5-1.9 46.7 47.1 2.9 32 76.7 80.0 3.3 19
2-2.9 24.2 20.4 2.5 36 86.3 84.3 5.8 10
3 9.0 10.4 0.9 14 61.7 53.1 9.9 3
Abbreviations: INR, international normalized ratio; SAC, sepsis-associated coagulopathy; SEM, standard error of the mean.
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between elevated INR and elevated aPTT in this patient pop-
ulation. However, this alteration in coagulation is not accom-
panied by predictable or consistent changes in levels of
individual coagulation factors in this patient population. Addi-
tionally, elevated INR is accompanied not only by bleeding risk
but also by thrombosis in this patient population, a risk that is
not demonstrable by analysis of traditional hemostatic para-
meters. This study underscores the need for an improved under-
standing of the relationship of hemostatic laboratory
parameters to the ongoing coagulation processes and the asso-
ciated risks of both bleeding and thrombosis specific to the
SAC patient population.
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